Overview

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with recurrent/relapsed diffuse large B-cell lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
SymBio Pharmaceuticals
Treatments:
Rituximab